The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
|
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [41] Conversion From Intravenous Epoprostenol Products To Inhaled Treprostinil For Pulmonary Arterial Hypertension
    Alnuaimat, H.
    Reardon, N. T.
    Cash, J. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [42] Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
    Yanaka, Kenichi
    Guillien, Alicia
    Soumagne, Thibaud
    Benet, Justin
    Piliero, Nicolas
    Picard, Francois
    Pison, Christophe
    Sitbon, Olivier
    Bouvaist, Helene
    Degano, Bruno
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
  • [43] Endothelin-1 Across the Lung Circulation in Patients With Pulmonary Arterial Hypertension and Influence of Epoprostenol Infusion
    Selimovic, Nedim
    Andersson, Bert
    Bergh, Claes-Hakan
    Sakiniene, Egidija
    Carlsten, Hans
    Rundqvist, Bengt
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (08): : 808 - 814
  • [44] Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
    Badesch, David B.
    McGoon, Michael D.
    Barst, Robin J.
    Tapson, Victor F.
    Rubin, Lewis J.
    Wigley, Fredrick M.
    Kral, Kenneth M.
    Raphiou, Ibrahim H.
    Crater, Glenn D.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) : 2244 - 2249
  • [45] Transition from Intravenous Epoprostenol to Treprostinil Due to Intolerable Side Effects in Patients With Pulmonary Arterial Hypertension
    Kikuchi, Hanako
    Goda, Ayumi
    Takeuchi, Kaori
    Inami, Takumi
    Kohno, Takashi
    Soejima, Kyoko
    Satoh, Toru
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 206 : 31 - 34
  • [46] Single Center Experience In Transitioning Pulmonary Arterial Hypertension Patients From Intravenous Epoprostenol To Oral Selexipag
    Safdar, Z.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [47] Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil
    Olsson, Karen
    Richter, Manuel
    Kamp, Jan C.
    Gall, Henning
    Heine, Alexander
    Ghofrani, Hossein-Ardeshir
    Fuge, Jan
    Ewert, Ralf
    Hoeper, Marius M.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [48] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    Barst, RJ
    Rubin, LJ
    Long, WA
    McGoon, MD
    Rich, S
    Badesch, DB
    Groves, BM
    Tapson, VF
    Bourge, RC
    Brundage, BH
    Koerner, SK
    Langleben, D
    Keller, CA
    Murali, S
    Uretsky, BF
    Clayton, LM
    Jobsis, MM
    Blackburn, SD
    Shortino, D
    Crow, JW
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05): : 296 - 301
  • [49] Description Of The Clinical, Functional And Hemodynamic Characteristics Of Patients With Pulmonary Arterial Hypertension And Chronic Thromboembolic Pulmonary Hypertension Treated With Intravenous Epoprostenol In Colombia
    Villaquiran-Torres, C.
    Orozco-Levi, M.
    Londono, A.
    Ortega, J.
    Gomez, J. E.
    Conde, R.
    Borda, C.
    Duenas-Villamil, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [50] Weaning and discontinuation of Epoprostenol in children with idiopathic, pulmonary arterial hypertension receiving concomitant bosentan
    Ivy, DD
    Doran, A
    Claussen, L
    Bingaman, D
    Yetman, A
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (07): : 943 - 946